Foghorn Therapeutics Inc. $FHTX Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC grew its holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX) by 36.5% in the 1st quarter, HoldingsChannel reports. The firm owned 406,425 shares of the company’s stock after purchasing an additional 108,689 shares during the quarter. Renaissance Technologies LLC’s holdings in Foghorn Therapeutics were worth $1,943,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in FHTX. Deutsche Bank AG increased its stake in Foghorn Therapeutics by 7.3% during the 4th quarter. Deutsche Bank AG now owns 27,421 shares of the company’s stock worth $148,000 after buying an additional 1,861 shares during the period. BNP Paribas Financial Markets lifted its holdings in Foghorn Therapeutics by 48.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock worth $35,000 after buying an additional 2,305 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Foghorn Therapeutics by 16.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,723 shares of the company’s stock valued at $88,000 after buying an additional 2,597 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Foghorn Therapeutics by 18.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,908 shares of the company’s stock valued at $84,000 after buying an additional 2,812 shares during the period. Finally, Strs Ohio grew its stake in shares of Foghorn Therapeutics by 120.5% in the fourth quarter. Strs Ohio now owns 8,600 shares of the company’s stock worth $46,000 after acquiring an additional 4,700 shares in the last quarter. Institutional investors and hedge funds own 61.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Foghorn Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded Foghorn Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.43.

Key Headlines Impacting Foghorn Therapeutics

Here are the key news stories impacting Foghorn Therapeutics this week:

• Positive Sentiment: Analysts’ average price target implies approximately 88.5% potential upside for FHTX. Although price targets are not always reliable, the expectation of meaningful appreciation may be supporting investor interest. Wall Street Analysts Believe Foghorn Therapeutics Could Rally 88.47%
• Positive Sentiment: HC Wainwright raised its Foghorn Therapeutics FY2026 EPS forecast to a loss of $0.91 per share from a projected loss of $1.06, and improved its FY2027 estimate to a loss of $0.84 from $0.90. While the company remains unprofitable, these revisions suggest somewhat better expected results in the next two years.
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior report, with a zero-day days-to-cover ratio. Because the data appears incomplete or anomalous, it provides little actionable information about short-selling pressure.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to a loss of $0.29 from $0.28 and its Q4 forecast to a loss of $0.23 from $0.21, indicating weaker expected near-term profitability.
• Negative Sentiment: The firm also reduced longer-term EPS forecasts, including FY2028 to a loss of $0.84 from $0.57, FY2029 to a loss of $0.84 from $0.04, and FY2030 to a loss of $0.72 from previously expected earnings of $0.36. These revisions point to a slower path toward profitability.

Foghorn Therapeutics Stock Performance

FHTX stock opened at $6.59 on Wednesday. The company’s 50 day moving average price is $4.83 and its 200 day moving average price is $4.97. Foghorn Therapeutics Inc. has a fifty-two week low of $3.27 and a fifty-two week high of $6.95. The firm has a market capitalization of $391.31 million, a price-to-earnings ratio of -6.72 and a beta of 2.89.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.14. The firm had revenue of $16.10 million during the quarter, compared to analyst estimates of $6.80 million. Equities analysts forecast that Foghorn Therapeutics Inc. will post -0.91 EPS for the current fiscal year.

Foghorn Therapeutics Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.